nevirapine has been researched along with Allergy, Drug in 48 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We modeled nevirapine (NVP) pharmacokinetics in HIV-infected Malawian patients to assess the relationship between drug exposure and patient characteristics, genetic polymorphisms, and development of hypersensitivity reaction (HSR)." | 7.80 | Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. ( Carr, DF; Chaponda, M; Dickinson, L; Heyderman, RS; Khoo, SH; Kumwenda, J; Lalloo, DG; Pirmohamed, M; van Oosterhout, JJ, 2014) |
| "Drug rash with eosinophilia and systemic symptoms (DRESS Syndrome) associated with nevirapine treatment has not been previously reported in children." | 7.74 | Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection. ( Barton, T; Ramilo, O; Santos, RP, 2007) |
| "The antiretroviral nevirapine is associated with hypersensitivity reactions in 6%-10% of patients, including hepatotoxicity, maculopapular exanthema, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)." | 3.85 | Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. ( Alfirevic, A; Borgiani, P; Bourgeois, S; Carr, DF; Castro, EM; Chaponda, M; Dandara, C; Deloukas, P; Haldenby, S; Heyderman, RS; Holden, A; Jones, AR; Kampira, E; Khoo, S; Lalloo, DG; Morris, AP; Munderi, P; Nelson, MR; Novelli, G; Pirmohamed, M; Rigden, DJ; Ssali, F; Takeshita, LY; van Oosterhout, JJ, 2017) |
| "We modeled nevirapine (NVP) pharmacokinetics in HIV-infected Malawian patients to assess the relationship between drug exposure and patient characteristics, genetic polymorphisms, and development of hypersensitivity reaction (HSR)." | 3.80 | Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. ( Carr, DF; Chaponda, M; Dickinson, L; Heyderman, RS; Khoo, SH; Kumwenda, J; Lalloo, DG; Pirmohamed, M; van Oosterhout, JJ, 2014) |
| "Drug rash with eosinophilia and systemic symptoms (DRESS Syndrome) associated with nevirapine treatment has not been previously reported in children." | 3.74 | Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection. ( Barton, T; Ramilo, O; Santos, RP, 2007) |
| "Rash is the most frequent adverse event associated with nevirapine." | 2.70 | Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. ( Blanco, JL; Boix, V; De Miguel, V; Domingo, P; Force, L; González, A; Knobel, H; Locutura, J; Márquez, M; Miró, JM; Rivero, A; Sanz, J, 2001) |
| "The rash is clearly immune-mediated in rats, and partial depletion of CD4(+) T cells, but not CD8(+) T cells, is protective." | 2.46 | Nevirapine hypersensitivity. ( Abdulla, D; Baban, A; Chen, J; Mannargudi, B; Popovic, M; Shenton, JM; Tharmanathan, T; Uetrecht, JP, 2010) |
| "Liver toxicity is one of the most relevant adverse effects of antiretroviral therapy." | 2.44 | Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. ( Mira, JA; Pineda, JA; Rivero, A, 2007) |
| "Nevirapine (NVP), is an HIV-1 antiretroviral with treatment-limiting hypersensitivity reactions (HSRs) associated with multiple class I and II HLA alleles." | 1.46 | Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. ( Bracey, A; Buus, S; Carrington, M; Chopra, A; Gaudieri, S; Haas, DW; Hunt, DF; Jing, Y; Kaever, T; Koelle, D; Malaker, SA; Mallal, S; McKinnon, EJ; Myers, P; Ostrov, DA; Pavlos, R; Peters, B; Phillips, EJ; Redwood, A; Restrepo, S; Rive, C; Schutte, R; Shabanowitz, J; Speers, E, 2017) |
| "Nevirapine-based ART was initiated in 820 women and baseline ALT or AST results were abnormal (≥ grade 1) in 113 (14%) women." | 1.36 | Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya. ( Bolu, O; Borkowf, CB; Brooks, JT; Intalapaporn, P; Kiarie, J; McConnell, MS; Mutsotso, W; Peters, PJ; Potter, D; Ratanasuwan, W; Stringer, J; Weidle, PJ; Zulu, I, 2010) |
| "By logistic regression, history of drug allergy apart from NVP (odds ratio [OR] 11." | 1.35 | Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash. ( Kiertiburanakul, S; Malathum, K; Sathapatayavongs, B; Sungkanuparph, S; Watcharananan, S, 2009) |
| " We investigated the relationship of NVP dosing with safety and efficacy." | 1.35 | Safety and efficacy of once-daily nevirapine dosing: a multicohort study. ( Battegay, M; Calmy, A; de Wolf, F; Hirschel, B; Hogg, RS; Lange, JM; Lima, VD; Montaner, JS; Nguyen, A; Reiss, P; Vallier, N; Wit, FW; Yip, B, 2009) |
| "By logistic regression, history of drug allergy (OR, 3." | 1.35 | Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. ( Chantratita, W; Charoenyingwattana, A; Kiertiburanakul, S; Mahasirimongkol, S; Sungkanuparph, S; Sura, T, 2008) |
| " All other patients have been taking nevirapine for more than 3 months without any adverse reaction." | 1.31 | Long-term safety and efficacy of nevirapine tolerance induction. ( Bousquet, J; Demoly, P; Fabre, J; Messaad, D; Reynes, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.25) | 18.2507 |
| 2000's | 27 (56.25) | 29.6817 |
| 2010's | 18 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prasertvit, P | 1 |
| Chareonyingwattana, A | 1 |
| Wattanakrai, P | 1 |
| Pavlos, R | 1 |
| McKinnon, EJ | 1 |
| Ostrov, DA | 1 |
| Peters, B | 1 |
| Buus, S | 1 |
| Koelle, D | 1 |
| Chopra, A | 1 |
| Schutte, R | 1 |
| Rive, C | 2 |
| Redwood, A | 1 |
| Restrepo, S | 1 |
| Bracey, A | 1 |
| Kaever, T | 1 |
| Myers, P | 1 |
| Speers, E | 1 |
| Malaker, SA | 1 |
| Shabanowitz, J | 1 |
| Jing, Y | 1 |
| Gaudieri, S | 1 |
| Hunt, DF | 1 |
| Carrington, M | 1 |
| Haas, DW | 1 |
| Mallal, S | 4 |
| Phillips, EJ | 2 |
| Sousa, MJ | 1 |
| Cadinha, S | 1 |
| Mota, M | 1 |
| Teixeira, T | 1 |
| Malheiro, D | 1 |
| Moreira da Silva, JP | 1 |
| Hu, K | 1 |
| Xiang, Q | 1 |
| Wang, Z | 1 |
| Mu, GY | 1 |
| Zhang, Z | 1 |
| Ma, LY | 1 |
| Xie, QF | 1 |
| Chen, SQ | 1 |
| Zhou, S | 1 |
| Zhang, XD | 1 |
| Cui, YM | 1 |
| Bayonne Kombo, ES | 1 |
| Gathse, A | 1 |
| Dickinson, L | 1 |
| Chaponda, M | 4 |
| Carr, DF | 4 |
| van Oosterhout, JJ | 4 |
| Kumwenda, J | 1 |
| Lalloo, DG | 4 |
| Pirmohamed, M | 4 |
| Heyderman, RS | 4 |
| Khoo, SH | 2 |
| Karlin, E | 1 |
| Phillips, E | 5 |
| Keane, NM | 1 |
| Pavlos, RK | 1 |
| McKinnon, E | 1 |
| Lucas, A | 1 |
| Blyth, CC | 1 |
| Dunn, D | 1 |
| Lucas, M | 1 |
| Cornejo Castro, EM | 1 |
| Jorgensen, AL | 2 |
| Khoo, S | 2 |
| Dandara, C | 2 |
| Kampira, E | 2 |
| Ssali, F | 3 |
| Munderi, P | 3 |
| Sanjeeva, GN | 1 |
| Sukanya, V | 1 |
| Pavithra, HB | 1 |
| Dodderi, SK | 1 |
| Rewari, BB | 1 |
| Govindaraj, M | 1 |
| Shivananda, S | 1 |
| Premalatha, R | 1 |
| Bourgeois, S | 1 |
| Takeshita, LY | 1 |
| Morris, AP | 1 |
| Castro, EM | 1 |
| Alfirevic, A | 2 |
| Jones, AR | 1 |
| Rigden, DJ | 1 |
| Haldenby, S | 1 |
| Novelli, G | 1 |
| Borgiani, P | 1 |
| Nelson, MR | 1 |
| Holden, A | 1 |
| Deloukas, P | 1 |
| Shear, NH | 1 |
| Milpied, B | 1 |
| Bruynzeel, DP | 1 |
| Roca, B | 1 |
| Kiertiburanakul, S | 2 |
| Malathum, K | 1 |
| Watcharananan, S | 1 |
| Sathapatayavongs, B | 1 |
| Sungkanuparph, S | 2 |
| Hoskins, JM | 1 |
| Roederer, MW | 1 |
| McLeod, HL | 1 |
| Kesselring, AM | 2 |
| Wit, FW | 4 |
| Sabin, CA | 1 |
| Lundgren, JD | 1 |
| Gill, MJ | 1 |
| Gatell, JM | 1 |
| Rauch, A | 2 |
| Montaner, JS | 4 |
| de Wolf, F | 3 |
| Reiss, P | 3 |
| Mocroft, A | 1 |
| Merk, HF | 1 |
| Calmy, A | 1 |
| Vallier, N | 1 |
| Nguyen, A | 1 |
| Lange, JM | 3 |
| Battegay, M | 1 |
| Lima, VD | 3 |
| Hirschel, B | 1 |
| Hogg, RS | 3 |
| Yip, B | 3 |
| Popovic, M | 1 |
| Shenton, JM | 1 |
| Chen, J | 1 |
| Baban, A | 1 |
| Tharmanathan, T | 1 |
| Mannargudi, B | 1 |
| Abdulla, D | 1 |
| Uetrecht, JP | 1 |
| Chasela, CS | 1 |
| Hudgens, MG | 1 |
| Jamieson, DJ | 1 |
| Kayira, D | 1 |
| Hosseinipour, MC | 1 |
| Kourtis, AP | 1 |
| Martinson, F | 1 |
| Tegha, G | 1 |
| Knight, RJ | 1 |
| Ahmed, YI | 1 |
| Kamwendo, DD | 1 |
| Hoffman, IF | 1 |
| Ellington, SR | 1 |
| Kacheche, Z | 1 |
| Soko, A | 1 |
| Wiener, JB | 1 |
| Fiscus, SA | 1 |
| Kazembe, P | 1 |
| Mofolo, IA | 1 |
| Chigwenembe, M | 1 |
| Sichali, DS | 1 |
| van der Horst, CM | 1 |
| Peters, PJ | 1 |
| Stringer, J | 1 |
| McConnell, MS | 1 |
| Kiarie, J | 1 |
| Ratanasuwan, W | 1 |
| Intalapaporn, P | 1 |
| Potter, D | 1 |
| Mutsotso, W | 1 |
| Zulu, I | 1 |
| Borkowf, CB | 1 |
| Bolu, O | 1 |
| Brooks, JT | 1 |
| Weidle, PJ | 1 |
| Snowden, WB | 1 |
| Walker, AS | 1 |
| Kityo, C | 1 |
| Mosteller, M | 1 |
| Kabuye, G | 1 |
| Thoofer, NK | 1 |
| Gilks, CF | 1 |
| Hughes, AR | 1 |
| Gutierrez, Mdel M | 1 |
| Mateo, MG | 1 |
| Vidal, F | 1 |
| Domingo, P | 2 |
| Gao, S | 1 |
| Gui, XE | 1 |
| Liang, K | 1 |
| Liu, Z | 1 |
| Hu, J | 1 |
| Dong, B | 1 |
| Castro, EC | 1 |
| Caumes, E | 1 |
| Bossi, P | 1 |
| Katlama, C | 1 |
| Bricaire, F | 1 |
| Martin, AM | 1 |
| Nolan, D | 2 |
| James, I | 1 |
| Cameron, P | 1 |
| Keller, J | 1 |
| Moore, C | 1 |
| Christiansen, FT | 1 |
| Martin, A | 1 |
| Almeida, CA | 1 |
| Littera, R | 1 |
| Carcassi, C | 1 |
| Masala, A | 1 |
| Piano, P | 1 |
| Serra, P | 1 |
| Ortu, F | 1 |
| Corso, N | 1 |
| Casula, B | 1 |
| La Nasa, G | 1 |
| Contu, L | 1 |
| Manconi, PE | 1 |
| Gatanaga, H | 2 |
| Yazaki, H | 1 |
| Tanuma, J | 1 |
| Honda, M | 1 |
| Genka, I | 1 |
| Teruya, K | 1 |
| Tachikawa, N | 1 |
| Kikuchi, Y | 1 |
| Oka, S | 2 |
| Rivero, A | 2 |
| Mira, JA | 1 |
| Pineda, JA | 1 |
| Gutiérrez, S | 2 |
| Jahnke, N | 2 |
| Harrigan, PR | 2 |
| Santos, RP | 1 |
| Ramilo, O | 1 |
| Barton, T | 1 |
| Raffi, F | 1 |
| Lewden, C | 1 |
| Chêne, G | 1 |
| Gras, L | 1 |
| Richter, C | 1 |
| van der Ende, ME | 1 |
| Brinkman, K | 1 |
| Charoenyingwattana, A | 1 |
| Mahasirimongkol, S | 1 |
| Sura, T | 1 |
| Chantratita, W | 1 |
| Hayden, A | 1 |
| Honda, H | 1 |
| Bourezane, Y | 1 |
| Salard, D | 1 |
| Hoen, B | 1 |
| Vandel, S | 1 |
| Drobacheff, C | 1 |
| Laurent, R | 1 |
| Podzamczer, D | 1 |
| Consiglio, E | 1 |
| Ferrer, E | 1 |
| Gudiol, F | 1 |
| Lanzafame, M | 1 |
| Rovere, P | 1 |
| De Checchi, G | 1 |
| Trevenzoli, M | 1 |
| Turazzini, M | 1 |
| Parrinello, A | 1 |
| Knobel, H | 1 |
| Miró, JM | 1 |
| Márquez, M | 1 |
| Force, L | 1 |
| González, A | 1 |
| De Miguel, V | 1 |
| Sanz, J | 1 |
| Boix, V | 1 |
| Blanco, JL | 1 |
| Locutura, J | 1 |
| Wood, R | 1 |
| Horban, A | 1 |
| Beniowski, M | 1 |
| Schmidt, RE | 1 |
| Gray, G | 1 |
| Lazzarin, A | 1 |
| Lafeuillade, A | 1 |
| Paes, D | 1 |
| Carlier, H | 1 |
| van Weert, L | 1 |
| de Vries, C | 1 |
| van Leeuwen, R | 1 |
| Bundow, D | 1 |
| Rosoff, L | 1 |
| Aboulafia, DM | 1 |
| Messaad, D | 1 |
| Reynes, J | 1 |
| Fabre, J | 1 |
| Bousquet, J | 1 |
| Demoly, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| EuroSIDA Prospective Observational Cohort Study on Clinical and Virological Outcome of European Patients Infected With HIV[NCT02699736] | 23,000 participants (Actual) | Observational [Patient Registry] | 1994-01-31 | Enrolling by invitation | |||
| HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health[NCT00164736] | Phase 3 | 2,369 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Pharmacokinetics and Safety of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants[NCT04862975] | 200 participants (Anticipated) | Observational | 2024-01-08 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for nevirapine and Allergy, Drug
| Article | Year |
|---|---|
Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; Female; HIV Infections; HLA Antigens; Hu | 2019 |
Genotyping for severe drug hypersensitivity.
Topics: Allopurinol; Amoxicillin-Potassium Clavulanate Combination; Carbamazepine; Dideoxynucleosides; Drug | 2014 |
A review of drug patch testing and implications for HIV clinicians.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; HIV Infections; Humans; Nevirapine; Patc | 2008 |
Pharmacogenomics of antiretrovirals.
Topics: Alkynes; Anti-Retroviral Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Ce | 2008 |
Drug skin metabolites and allergic drug reactions.
Topics: Animals; Anticonvulsants; Antigen Presentation; Cytochrome P-450 Enzyme System; Dermatitis, Allergic | 2009 |
Nevirapine hypersensitivity.
Topics: Animals; Anti-HIV Agents; Biotransformation; Disease Models, Animal; Drug Hypersensitivity; Exanthem | 2010 |
The toxicogenetics of antiretroviral therapy: the evil inside.
Topics: Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides | 2011 |
[Antiretroviral-induced toxiderma in HIV-infected patients].
Topics: Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; | 2003 |
Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again.
Topics: Animals; Anti-HIV Agents; Biomarkers; Dideoxynucleosides; Drug Hypersensitivity; HIV-1; Humans; Nevi | 2006 |
Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
Topics: Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; Chemical | 2007 |
Pharmacogenetic information derived from analysis of HLA alleles.
Topics: Alleles; Animals; Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; HLA Antigens; Humans; | 2008 |
5 trials available for nevirapine and Allergy, Drug
| Article | Year |
|---|---|
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Hypersensitivity; Gene Frequen | 2011 |
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies | 2008 |
Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study.
Topics: Adult; Double-Blind Method; Drug Hypersensitivity; Exanthema; Female; Humans; Male; Middle Aged; Nev | 2001 |
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
Topics: Adult; Anti-HIV Agents; Anti-Inflammatory Agents; Dideoxynucleosides; Drug Hypersensitivity; Female; | 2001 |
32 other studies available for nevirapine and Allergy, Drug
| Article | Year |
|---|---|
Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; HIV; Humans; Nevirapine; Patch Tests; Pr | 2017 |
Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles.
Topics: Alleles; Anti-HIV Agents; Case-Control Studies; Disease Susceptibility; Drug Hypersensitivity; Histo | 2017 |
Hypersensitivity to antiretroviral drugs.
Topics: Anti-HIV Agents; Drug Hypersensitivity; Emtricitabine; Female; HIV Infections; Humans; Male; Middle | 2018 |
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazi | 2013 |
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Biotransformation; Black People; Cytochrome P | 2014 |
HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity.
Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; Drug Hypersensitivity | 2014 |
CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Cohort Studies; Cytochrome P-450 CYP2B6; Drug Hypersen | 2014 |
Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes | 2015 |
Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.
Topics: Adult; Africa South of the Sahara; Aged; Anti-HIV Agents; Biomarkers; Black People; Case-Control Stu | 2017 |
Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Chi-Square Distribution; Cohort | 2009 |
Nevirapine hypersensitivity reaction: will the real HLA please stand up?
Topics: Alleles; Drug Hypersensitivity; HLA Antigens; Humans; Nevirapine; Risk Factors | 2009 |
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Hypersensi | 2009 |
Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Drug Hypersensitivity | 2009 |
Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; CD4 Lymphocyte Count; Chemical | 2010 |
HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alleles; Anti-HIV Agents; Asian People; CD4 Lymphocyte Co | 2012 |
Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; Drug Hypersensitivity; Female; Gene Freque | 2013 |
Side effects. Severe nevirapine rash found more likely in women than men.
Topics: Drug Hypersensitivity; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhib | 2001 |
Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts.
Topics: Adult; Cohort Studies; Drug Hypersensitivity; Female; Genetic Predisposition to Disease; HLA Antigen | 2005 |
HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.
Topics: Adolescent; Adult; Drug Hypersensitivity; Female; Gene Frequency; Haplotypes; Hepatitis C; Histocomp | 2006 |
HLA-Cw8 primarily associated with hypersensitivity to nevirapine.
Topics: Adult; Anti-HIV Agents; Drug Hypersensitivity; Female; Genetic Predisposition to Disease; HIV Infect | 2007 |
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru | 2007 |
Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection.
Topics: Anti-HIV Agents; Child; Drug Hypersensitivity; Eosinophilia; Exanthema; Female; HIV Infections; HIV- | 2007 |
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Hypersensitivity; Hepatitis C, Chronic; HIV Infe | 2008 |
Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings.
Topics: Adult; Body Weight; Case-Control Studies; CD4 Lymphocyte Count; Developing Countries; Drug Hypersens | 2008 |
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.
Topics: Anti-HIV Agents; Drug Hypersensitivity; Hepatitis C, Chronic; HIV Infections; Humans; Nevirapine | 2008 |
DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.
Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination; Eosinophil | 1998 |
Efavirenz associated with corticosteroids in patients with previous severe hypersensitivity reaction due to nevirapine.
Topics: Adrenal Cortex Hormones; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersen | 2000 |
Gender difference in Nevirapine-associated rash.
Topics: Anti-HIV Agents; Drug Hypersensitivity; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Tr | 1999 |
Desensitization to Nevirapine.
Topics: Anti-HIV Agents; Desensitization, Immunologic; Drug Hypersensitivity; HIV Infections; Humans; Nevira | 1999 |
Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy.
Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Hypersensitivity; Eosinophilia; Exanthema; HIV Infectio | 2001 |
Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur | 2001 |
Long-term safety and efficacy of nevirapine tolerance induction.
Topics: Adult; Aged; Drug Eruptions; Drug Hypersensitivity; Humans; Immune Tolerance; Male; Middle Aged; Nev | 2002 |